BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16542849)

  • 1. Anti-TNF therapies in the management of acute and chronic uveitis.
    Hale S; Lightman S
    Cytokine; 2006 Feb; 33(4):231-7. PubMed ID: 16542849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
    Sfikakis PP
    Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
    Braun J; Baraliakos X; Listing J; Sieper J
    Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
    Tognon S; Graziani G; Marcolongo R
    Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
    Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
    Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-TNF-alpha treatment and spondyloarthropathies].
    Braun Y; Balbir-Gurman A
    Harefuah; 2002 Nov; 141(11):965-8, 1010. PubMed ID: 12476631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice.
    Elewaut D; Matucci-Cerinic M
    Rheumatology (Oxford); 2009 Sep; 48(9):1029-35. PubMed ID: 19561158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.
    Theodossiadis PG; Markomichelakis NN; Sfikakis PP
    Retina; 2007; 27(4):399-413. PubMed ID: 17420690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital.
    Petropoulos IK; Vaudaux JD; Guex-Crosier Y
    Klin Monbl Augenheilkd; 2008 May; 225(5):457-61. PubMed ID: 18454398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab in the treatment of refractory posterior uveitis.
    Joseph A; Raj D; Dua HS; Powell PT; Lanyon PC; Powell RJ
    Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable response to high-dose infliximab for refractory childhood uveitis.
    Kahn P; Weiss M; Imundo LF; Levy DM
    Ophthalmology; 2006 May; 113(5):860-4.e2. PubMed ID: 16545455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
    Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
    Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review.
    Atzeni F; Sarzi-Puttini P; Doria A; Iaccarino L; Capsoni F
    Autoimmun Rev; 2005 Mar; 4(3):144-52. PubMed ID: 15823500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
    Gisondi P; Cotena C; Tessari G; Girolomoni G
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis.
    Monnet D; Moachon L; Dougados M; Brézin AP
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):393-7. PubMed ID: 16932725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor inhibitors in ankylosing spondylitis.
    Reed MR; Taylor AL
    Intern Med J; 2008 Oct; 38(10):781-9. PubMed ID: 18422565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.